Health
CytoSorbents Leads a New Era in Sepsis Treatment
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights new studies that demonstrate the vital and evolving role of CytoSorb® therapy in the treatment of sepsis and septic shock – among the deadliest challenges in critical care medicine. Recent data demonstrate early and intensive use of CytoSorb therapy improves clinical outcomes for patients suffering from these conditi
About this update from Cytosorbents Corporation
[{"type":"text","content":"CytoSorbents highlights the vital and evolving role of CytoSorb® in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10th ","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights new studies that demonstrate the vital and evolving role of CytoSorb® therapy in the treatment of sepsis and septic shock – among the deadliest challenges in critical care medicine. Recent data demonstrate early and intensive use of CytoSorb therapy improves clinical outcomes for patients suffering from these conditions. Today, the Company provides an overview of CytoSorb's unique approach and the evolving data supporting its use, in advance of its September 10, 2025 World Sepsis Day Global Webinar – being held in commemoration of Sepsis Awareness Month and World Sepsis Day in September. Dr. Phillip Chan, MD, PhD, Chief Executive Officer, will host a special presentation with physician-user guests to discuss CytoSorb therapy best practices and its impact in the fight against sepsis.","length":1036,"tagName":"p"},{"type":"image","alt":"CytoSorb Device","displaySize":"","headline":null,"caption":"CytoSorb Device","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":288,"url":"https://media.zenfs.com/en/prnewswire.com/4d56b6dc4deb0c53a5899a11100d2b22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PHjyhsNeOS3WQfuZrmTw0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUwODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4d56b6dc4deb0c53a5899a11100d2b22","width":400,"height":288}},"href":"https://mma.prnewswire.com/media/2741797/CYTOSORBENTS_CORP__CytoSorb_Device.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Chan explains, "For more than a decade, CytoSorbents has partnered with clinicians and scientists to improve the treatment of sepsis and septic shock by supplementing traditional antibiotic therapy with the powerful, broad-spectrum blood purification capability of CytoSorb. While antibiotics target the source of infection, CytoSorb addresses the other major drivers of septic shock, including se...